Phaseline

Companies › Shanghai Euhearing Therapeutics

Shanghai Euhearing Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EHT102 Injection
Dual-vector gene therapy for OTOF gene replacement
OTOFPhase 1Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)Jun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07288580EHT102 InjectionPhase 1Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)OtherJun 2028

Targets

OTOF (1)

Companies with the same targets

Eli Lilly Regeneron Pharmaceuticals Sensorion

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.